|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2002-7-19
|
|
pubmed:abstractText |
High-dose (400 mg.) oral ketoconazole 3 times daily with replacement doses of hydrocortisone has become a standard treatment option for patients with advanced prostate cancer which progresses after androgen deprivation. However, toxicity can hinder the ability to deliver treatment and the cost of the regimen can be substantial. Therefore, a prospective phase II study was conducted to assess the efficacy and safety of a regimen of low dose (200 mg.) oral ketoconazole 3 times daily with replacement doses of hydrocortisone in men with androgen independent prostate cancer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0022-5347
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
168
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
542-5
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:12131305-Adenocarcinoma,
pubmed-meshheading:12131305-Aged,
pubmed-meshheading:12131305-Aged, 80 and over,
pubmed-meshheading:12131305-Androgen Antagonists,
pubmed-meshheading:12131305-Androgens,
pubmed-meshheading:12131305-Disease Progression,
pubmed-meshheading:12131305-Dose-Response Relationship, Drug,
pubmed-meshheading:12131305-Drug Administration Schedule,
pubmed-meshheading:12131305-Drug Therapy, Combination,
pubmed-meshheading:12131305-Humans,
pubmed-meshheading:12131305-Hydrocortisone,
pubmed-meshheading:12131305-Ketoconazole,
pubmed-meshheading:12131305-Male,
pubmed-meshheading:12131305-Middle Aged,
pubmed-meshheading:12131305-Prognosis,
pubmed-meshheading:12131305-Prostate-Specific Antigen,
pubmed-meshheading:12131305-Prostatic Neoplasms,
pubmed-meshheading:12131305-Treatment Outcome,
pubmed-meshheading:12131305-Tumor Markers, Biological
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer.
|
|
pubmed:affiliation |
University of California, San Francisco, UCSF Comprehensive Cancer Center, San Francisco, California, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
